Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms

The Department of Leukemia has established the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms (MPNs) as a distinct operational unit within the Leukemia Department and Leukemia Outpatient Center. The goal of the Clinical Research Center for MPNs is to develop novel effective therapies for MPNs that will significantly improve patient's outcomes and quality of life, provide exceptional patient care and ultimately cure MPNs.

The Hanns A. Pielenz Clinical Research Center for MPNs has become the largest in the world for referrals of MPN patients and clinical research. Medications that have become the global standard of care for myelofibrosis (JAK1/2 inhibitor ruxolitinib) were developed at the Clinical Research Center for MPNs. We see more than 250 new patients with MPNs annually, far more than any other clinical center in the world, and are continuously engaged in clinical research studies to develop novel therapies for our MPN patients.

The main goals of the Hanns A. Pielenz Clinical Research Center for MPNs include:

• Conduct clinical trials to evaluate novel agents for patients with MPNs and provide exceptional patient care: For a comprehensive overview of novel MPN medications in clinical development at the Clinical Research Center of MPNs, please visit Current MPN Research.
• Maintain a centralized tissue bank and database for collection and storage of patient specimens, which are valuable resources to conduct basic and translational research in MPNs.
• Educate patients, caregivers, physicians and the community at large about the latest findings regarding research and treatments in MPNs.

Contact Information

New Patient Referral Line: 1-85-LEUKEMIA/1-855-385-3642 (Toll-Free) or 713-563-2000
Leukemia Clinic Phone: 713-792-8760
Leukemia Department Phone: 713-792-7305
Clinic Fax: 713-792-6191
Department Fax: 713-794-4297

Business hours: 8 a.m.-5 p.m., Monday-Friday